Targeting of solid tumors and blood malignancies by antibody-based therapies — EGFR-pathway as an example

Targeting of solid tumors and blood malignancies by antibody-based therapies — EGFR-pathway as an example

Bibliographic Details
Main Authors:	Krzemieniecki Krzysztof, Szpyt Elzbieta, Rashedi Iran, Gawron Katarzyna, Los Marek
Format:	Article
Language:	English
Published:	De Gruyter 2006-06-01
Series:	Open Life Sciences
Subjects:	ovarex theragyn triab zamyl zevalin
Online Access:	https://doi.org/10.2478/s11535-006-0014-6

Similar Items

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
by: Christos Sachpekidis, et al.
Published: (2019-09-01)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
by: Gabriele Antonarelli, et al.
Published: (2021-08-01)

KIR Genes and their Ligands Predict the Response to Anti-2 EGFR Monoclonal Antibodies in Solid Tumors
by: Cristina Morales-Estevez, et al.
Published: (2016-12-01)

The significance of the EGFR pathway in malignant pleural mesothelioma
by: Agarwal, Vijay
Published: (2012)

An EGFR‐targeting antibody–drug conjugate LR004‐VC‐MMAE: potential in esophageal squamous cell carcinoma and other malignancies
by: Xin‐yue Hu, et al.
Published: (2019-02-01)

The role of DNase X in skeletal muscle addressed by targeted disruption of the gene in a mouse model
by: Rashedi, Iran.
Published: (2013)

The role of DNase X in skeletal muscle addressed by targeted disruption of the gene in a mouse model
by: Rashedi, Iran.
Published: (2013)

Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
by: Shang-Gin Wu, et al.
Published: (2011-01-01)

Anti-EGFR Antibody Reduces Lung Nodules by Inhibition of EGFR-Pathway in a Model of Lymphangioleiomyomatosis
by: Elena Lesma, et al.
Published: (2015-01-01)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.
by: Alessandro eOttaiano, et al.
Published: (2013-01-01)

Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression
by: Stefanie Derer, et al.
Published: (2012-03-01)

Increased mean corpuscular volume as a predictor of response during bevacizumab treatment
by: Zygulska Lidia Aneta, et al.
Published: (2012-01-01)

Bisecting N-Acetylglucosamine on EGFR Inhibits Malignant Phenotype of Breast Cancer via Down-Regulation of EGFR/Erk Signaling
by: Lanming Cheng, et al.
Published: (2020-06-01)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
by: Koki Makabe, et al.
Published: (2021-03-01)

EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy
by: Mauro Moroni, et al.
Published: (2011-12-01)

Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma
by: Gatalica Zoran, et al.
Published: (2010-10-01)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
by: Renba Liang MD, et al.
Published: (2021-01-01)

Biomarker and Therapeutic Studies of Antibodies and Small Molecules that Target EGFR
by: Mutsaers, Anthony James
Published: (2010)

Biomarker and Therapeutic Studies of Antibodies and Small Molecules that Target EGFR
by: Mutsaers, Anthony James
Published: (2010)

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
by: Fernando Concha-Benavente, et al.
Published: (2017-05-01)

Balancing Efficacy and Selectivity of Bispecific c-METxEGFR Antibodies
by: Sellmann, Carolin
Published: (2016)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
by: Ken Uchibori, et al.
Published: (2017-03-01)

Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
by: Pedicini Piernicola, et al.
Published: (2012-06-01)

A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors
by: Tae Kyu Chung, et al.
Published: (2021-05-01)

Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS
by: Jeong Eun Kim, et al.
Published: (2018-04-01)

Management of acneiform rash associated with anti-EGFR monoclonal antibody treatment
by: E. A. Shatokhina, et al.
Published: (2020-12-01)

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
by: Wen-Qi Cai, et al.
Published: (2020-07-01)

Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134
by: Mika K. Kaneko, et al.
Published: (2018-07-01)

MAXIMIZATION OF DNA DAMAGE TO MGMT(+) EGFR(+) GBM CELLS USING OPTIMAL COMBINATION OF TEMOZOLOMIDE-ANTI EGFR MONOCLONAL ANTIBODY NIMOTUZUMAB
by: M. A. M. Inggas, et al.
Published: (2015-09-01)

Correction: modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
by: Pedicini Piernicola, et al.
Published: (2012-08-01)

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
by: Jason J. Zoeller, et al.
Published: (2020-11-01)

Cytomegalovirus infection in solid malignancies
by: Amit Kumar Agrawal, et al.
Published: (2020-01-01)

Vorinostat in solid and hematologic malignancies
by: Richon Victoria M, et al.
Published: (2009-07-01)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
by: Xiao‐Li Wei, et al.
Published: (2020-08-01)

Assessment of the tumor malignancy after immunotherapy combined with EGFR-TKIs drug treatment of EGFR-mutant advanced non-small cell lung cancer
by: Lu Bai1, et al.
Published: (2017-04-01)

Targeting Malignant Brain Tumors with Antibodies
by: Rok Razpotnik, et al.
Published: (2017-09-01)

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
by: Junyeong Jin, et al.
Published: (2018-05-01)

Therapeutic Efficacy of GC1118, a Novel Anti-Egfr Antibody, against Glioblastoma with High Egfr Amplification in Patient-Derived Xenografts
by: Kyoungmin Lee, et al.
Published: (2020-10-01)

Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer.
by: Guiyang Jiang, et al.
Published: (2013-01-01)

A modified platform for bi-specific antibody and characterizations of an anti-EGFR/c-Met bi-specific antibody
by: 黃俊惟
Published: (2012)